

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

**The impact of side effect framing on COVID-19 booster vaccine intentions in an Australian sample.**

*Barnes, K.<sup>1</sup>, Faasse, K.<sup>2</sup>, & Colagiuri, B.<sup>1</sup>*

*<sup>1</sup>School of Psychology, The University of Sydney, Sydney, NSW, Australia*

*<sup>2</sup>School of Psychology, The University of New South Wales, Sydney, NSW, Australia*

**Corresponding Author:**

Dr. Kirsten Barnes,  
School of Psychology, A18  
University of Sydney  
NSW 2006  
Australia

Email: [kirsten.barnes@sydney.edu.au](mailto:kirsten.barnes@sydney.edu.au). NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## Abstract

25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

**Objective:** To evaluate the effect of presenting positively attribute-framed side effect information on COVID-19 booster vaccine intention relative to standard negatively-framed wording and a no-intervention control.

**Design setting and participants:** A representative sample of Australian adults ( $N=1,204$ ) were randomised to one of six conditions within a factorial design: Framing (Positive; Negative; Control) \* Vaccine (Familiar (Pfizer); Unfamiliar (Moderna)).

**Intervention:** Negative Framing involved presenting the likelihood of experiencing side effects (e.g., heart inflammation is very rare, 1 in every 80,000 will be affected), whereas Positive Framing involved presenting the same information but as the likelihood of *not* experiencing side effects (e.g., 79,999 in every 80,000 will not be affected).

**Primary Outcome:** Booster vaccine intention measured pre- and post-intervention.

**Results:** Positive Framing ( $M=75.7$ ,  $SE=0.9$ , 95% CI[73.9, 77.4]) increased vaccine intention relative to Negative Framing ( $M=70.7$ ,  $SE=0.9$ , 95% CI[68.9, 72.4]) overall ( $F(1, 1192)=4.68$ ,  $p=.031$ ,  $\eta_p^2=.004$ ). Framing interacted with Vaccine and Baseline Intention ( $F(2, 1192)=6.18$ ,  $p=.002$ ,  $\eta_p^2=.01$ ). Positive Framing was superior, or at least equal, to Negative Framing and Control at increasing Booster Intention, irrespective of the participants pre-intervention level of intent. Side effect worry and perceived severity mediated the effect of Positive vs. Negative Framing across vaccines.

**Conclusion:** Positive framing of side effect information appears superior for increasing vaccine intention relative to the standard negative wording currently used.

**Pre-registration:** See: [aspredicted.org/LDX\\_2ZL](https://aspredicted.org/LDX_2ZL)

## Introduction

47  
48 Reasons for vaccine hesitancy are multifaceted<sup>1,2</sup>. However, side effect apprehension is a  
49 primary factor<sup>1</sup>, with previous experience of COVID-19 vaccine side effects shown to reduce  
50 later booster vaccine intention<sup>3</sup>. To achieve effective societal protection from COVID-19,  
51 behavioural intervention is required to reduce apprehension and increase vaccine acceptance<sup>4</sup>.

52 Side effect information framing has been suggested as such an intervention<sup>5</sup>. Standard  
53 negative wording is typically used to present side effect information on official sources such as  
54 the Australian Government and AusVaxSafety (a national vaccine safety system) websites. For  
55 example, “33% of people *were affected* by headaches after their second Pfizer dose”. Our  
56 research suggests negative wording of this type may increase hesitancy relative to positive  
57 wording (i.e., presenting the number *not affected*)<sup>6</sup>. Further, consistent with prior research  
58 demonstrating that vaccine relevance or familiarity moderates the effect of framing<sup>7,8</sup>, this effect  
59 was especially pronounced when associated with an unfamiliar vaccine<sup>6</sup>.

60 Updating currently presented side effect information with a positively framed  
61 counterpart is both easy to implement and does not violate patient informed consent (given that  
62 statistical information is equivalent to the standard negative form)<sup>9</sup>. As such, framing may be  
63 particularly well suited to increasing vaccine acceptance. However, in our previous research  
64 conducted in a UK sample, framing was applied to side effect frequency bands presented in  
65 manufacturer Patient Information Leaflets (PILs). This statistical information is commonly  
66 presented in the EU, but not in Australia.

67 In the present study, we therefore tested an intervention more similar to current  
68 Australian sources of side effect information (such as AusVaxSafety). Information detailing  
69 severe side effects (heart inflammation and anaphylaxis<sup>10,11</sup>) and side effect-induced daily  
70 disruptions (data from AusVaxSafety) were presented to participants who had received two  
71 doses of a COVID-19 vaccine but no booster. This information was presented using the

72 standard negative wording (Negative Framing group), positive wording (Positive Framing  
73 group), or not at all (No-Intervention Control group).

74 Pre-registered hypotheses were as follows: 1) being presented with objective side effect  
75 information, irrespective of type of framing, would increase Booster Intention relative to  
76 Control; 2) Positive Framing would increase Booster Intention relative to Negative Framing; 3)  
77 Framing (Positive or Negative) would interact with Vaccine Familiarity, with the effect of  
78 Positive Framing on Booster Intention being stronger for a less familiar vaccine (i.e., Moderna  
79 relative to Pfizer: at the time of data collection ~10,000,000 doses of Moderna had been  
80 administered compared to 38,454,860 doses of Pfizer). Secondary-outcomes were explored as  
81 potential mediators of the framing effect<sup>9,12,13</sup> (see Supplementary Materials: S1.1).

82

## 83 **Methods**

### 84 **Participants**

85 Participants ( $N=1,204$ ) were recruited via Pureprofile, an ISO-certified panel provider.  
86 Inclusion criteria were: 1) 18+ years of age; 2) residing in Australia; 3) self-reported English  
87 fluency; 4) two doses of a COVID-19 vaccine; 5) no booster vaccine. Data were collected  
88 between 3<sup>rd</sup>–13<sup>th</sup> December 2021, just prior to the Omicron outbreak in Australia. Participants  
89 received \$2 for a 10-minute survey. All procedures in this pre-registered study  
90 ([aspredicted.org/LDX\\_2ZL](https://aspredicted.org/LDX_2ZL)) were approved by the University of Sydney Human Research  
91 Ethics Committee (reference, 2021/871), and all participants provided informed consent.  
92 Reporting is consistent with STROBE guidelines (Supporting Information: S1.2).

### 93 **Data Collection**

94 Data were collected on Pureprofile's inhouse platform. Stratification and randomisation  
95 (via random number generation) occurred via inbuilt code. Quotas were set for a minimum  
96  $N=200$  in each experimental condition (details below). All items required a response before

97 advancement. Several additional items concerning COVID-19 were collected prior to  
98 randomisation for a separate pre-registered study ([aspredicted.org/XSS\\_ZD1](https://aspredicted.org/XSS_ZD1)).

### 99 **Design**

100 Participants were stratified by their previous two COVID-19 vaccine doses  
101 (2xPfizer/2xAstraZeneca/Combination) and randomised to one of six experimental conditions in  
102 a 3 (Framing: Positive, Negative, Control) by 2 (Vaccine: Familiar(Pfizer) vs.  
103 Unfamiliar(Moderna)) factorial design.


104 The primary outcome was COVID-19 Booster Intention post-intervention for the  
105 assigned vaccine (either Pfizer or Moderna). The following secondary outcomes were measured  
106 to test for mediation of the framing effect: 1) Side Effect Worry; 2) Side Effect Severity; 3)  
107 Booster Protection. Two additional outcomes were measured. The first was Booster Intention  
108 for the “unassigned” vaccine (for the Framing groups, this was the vaccine for which they  
109 received no side-effect information; for the Control group, this was simply the other vaccine).  
110 This was used to explore possible generalisation of the framing effect to the other vaccine. The  
111 second was familiarity with the side effects of the Pfizer and Moderna vaccines measured pre-  
112 intervention. This was used to confirm that participants’ responses reflected the assumed  
113 Familiarity with each vaccine (i.e., Familiar/Pfizer>Unfamiliar/Moderna). All measures were  
114 rated on 100-point Visual Analogue Scale (VAS).

### 115 **Framing Intervention**

116 The intervention occurred in five stages. In stage 1, participants selected whether ‘daily  
117 disruptions’ or ‘serious side effects’ were their primary vaccination concern. In stage 2, they  
118 estimated the percentage of the population they believed would experience six side effects  
119 common to both the Pfizer and Moderna vaccine (i.e., local reaction, fatigue, headache, muscle  
120 or joint pain, gastrointestinal symptoms, fever) after receiving the framed vaccine. In stage 3,  
121 they were shown their responses from stage 2 against veridical percentages from Australian  
122 population data (derived from AusVaxSafety; 8<sup>th</sup> November 2021) for 1 minute. Stages 2 and 3

123 were performed in order to encourage participants to engage with and process the presented side  
124 effect information. The primary components of the intervention occurred in stages 4 and 5. In  
125 stage 4, participants viewed framed information (either positive or negative depending on group  
126 assignment) in the form of infographics regarding ‘daily disruptions’ from side effects. In stage  
127 5 this was also done regarding ‘serious side effects’ (estimates from<sup>10,11</sup>). Stages 4 and 5 were  
128 displayed for 30 seconds each. The exact order of presentation for stages 4 and 5 depended on  
129 the participant’s primary concern from stage 1. For example, if they indicated that they were  
130 more concerned with ‘daily disruptions’ then that information was first presented at stage 4.

131 The information presented to the Positive and Negative framing groups differed only in  
132 terms of whether this information stated the likelihood of experiencing or *not* experiencing the  
133 described side effect. Those assigned to the Negative Framing group saw ‘standard’ wording  
134 regarding side effects (e.g., Heart Inflammation: occurrence is very rare, 1 in every 80,000 will  
135 be affected), while those in the Positive Framing group saw the logical inverse (e.g., occurrence  
136 is very rare, 79,999 in every 80,000 *will not be affected*). Example infographics are displayed in  
137 Figure 1 (all infographics presented in S1.4). Framed information was not presented to the  
138 Control group. Instead, participants undertook an activity of their choosing for an equivalent  
139 intervention duration (2 minutes).




140  
141 Figure 1: Example materials used to present side effect information to those who received  
142 Positive Framing of the Unfamiliar vaccine (i.e., Moderna). 1a demonstrates the wording when  
143 presenting estimated and actual prevalence rates for the six common side effects, 1b concerns  
144 daily disruptions, and 1c serious adverse events from vaccination.

## 146 Procedure

147 Prior to randomisation, all participants provided demographic information, as well as  
148 vaccine and COVID-19 history (see Supporting Information (S1.3) for survey items). They also  
149 completed baseline measures for the primary (Booster Intention) and secondary outcomes,  
150 before being assigned to a condition. Please note, Baseline Intention was collected for both  
151 vaccines (Pfizer and Moderna). Dependent on randomisation, one of these ratings became the  
152 baseline for the framed vaccine, and the other the ‘unassigned’ vaccine (i.e., to explore  
153 generalisation).

154 Following group assignment, framing information (positive or negative) regarding side-  
155 effect likelihood for the assigned vaccine was presented to those in the intervention groups. All  
156 participants subsequently provided post-manipulation ratings for primary and secondary  
157 outcomes. See Figure 2 for a visual representation of the Procedure.



158  
159 Figure 2: Sample size, item wording, and experimental design (example: Unfamiliar/Positive  
160 Frame). Participants provided Baseline Booster Intention ratings for both vaccines (Pfizer and  
161 Moderna). Dependent on randomisation, one became the baseline for the framed vaccine and  
162 the other to explore generalisation of the framing effect (i.e., to unassigned vaccine).  
163 Participants were stratified by previous vaccine and randomised to one of six groups (2\*3  
164 factorial design). Those receiving Positive or Negative Framing underwent a manipulation with  
165 five stages: rating of primary concerns; active estimation of side effects; presentation of  
166 estimated side effects against population data; framed information regarding daily disruptions;  
167 framed information regarding serious side effects. Pre-registered analysis of all secondary  
168 outcomes are presented as Supporting Information (S1.1).



## 169 **Analysis and Sample**

170 Statistical analysis was performed using R (version 4.1.1). Primary analysis was a  
171 3(Framing)\*2(Vaccine) ANCOVA on post-intervention Booster Intention. Pre-specified  
172 orthogonal contrasts were: Contrast1 (Control vs. Framing [Positive and Negative combined]);  
173 Contrast2 (Positive vs. Negative). Differences in baseline Booster Intention (the covariate) were  
174 observed with Vaccine Familiarity ( $F(1, 1198)=172.49, p<.0001, \eta_p^2=.13$ ). As such, interactions  
175 between the covariate and manipulated variables (i.e., Framing and Familiarity) were included  
176 in the model, as recommended<sup>14,15</sup>. Mediation using the Lavaan package was performed using  
177 the secondary outcomes (Side Effect Worry; Side Effect Severity; Booster Protection).

178 Sample size was calculated via an *a priori* power analysis (95% power,  $\alpha=.05$ , effect  
179 size  $f^2=0.02$ ) for a separate concurrent study run that contained more predictors ( $N=9$ ), and  
180 therefore required more power (see study pre-registration).

181

## 182 **Results**

### 183 **Sample**

184 A total of 2,639 participants expressed interest. Of these, 998 did not meet inclusion  
185 criteria, 3 terminated at consent, 296 withdrew before completion, and 138 were excluded on  
186 pre-registered quality-control criteria (see S1.5). The final sample included 1,204 participants.

### 187 **Demographics**

188 Demographic information, COVID-19 exposure and vaccination history can be found in  
189 Table 1. Participant frequency by SA4 postal region is presented in Figure 3.


190

191 Table 1: Sample descriptive statistics presented against population data generated from the  
 192 Australian Bureau of Statistics, Education and Work Dataset 2021. *Nb*: Education sums to  
 193 109% due to calculation relying on separate ISCED and ASCED items to calculates estimates  
 194 for Primary and High School completers. Dashes denote unavailable population data.  
 195

	<b>Control Familiar</b> <i>N=201</i>	<b>Control Unfamiliar</b> <i>N=200</i>	<b>Negative Familiar</b> <i>N=201</i>	<b>Negative Unfamiliar</b> <i>N=201</i>	<b>Positive Familiar</b> <i>N=200</i>	<b>Positive Unfamiliar</b> <i>N=201</i>	<b>All Respondents</b> (%)	<b>Australian population</b> (%)
<b>Demographic Information</b>								
<b>State/territory</b>								
New South Wales	68	64	62	67	65	53	31.5	31.7
Victoria	48	48	58	52	54	57	26.3	26.3
Queensland	42	42	36	42	37	46	20.3	20.0
Western Australia	21	17	16	19	21	27	10.0	10.4
South Australia	12	23	16	11	18	10	7.5	6.9
Tasmania	5	0	8	4	6	3	2.2	2.1
Australian Capital Territory	5	4	4	5	2	2	1.8	1.7
Northern Territory	0	2	1	1	0	0	0.3	0.8
<b>Region</b>								
Metro	153	147	147	147	129	140	71.7	67.7
Regional	48	53	54	54	71	61	28.3	32.3
<b>Employment</b>								
Employed full-time	85	79	88	88	78	82	41.5	49.4
Employed part-time	40	47	35	36	35	31	18.6	21.7
Self employed	6	9	5	9	9	8	3.8	-
Unemployed (looking)	9	9	10	13	7	14	5.1	1.3
Carer	12	10	7	12	14	13	5.6	-
Student	4	9	9	6	9	6	3.6	-
Retired	44	37	45	37	47	46	21.3	-
Other	1	0	2	0	1	1	0.4	-
<b>Education</b>								
Primary school	1	0	0	1	2	0	0.3	4.5
High school	51	58	46	53	57	60	27.0	45.2
Technical certificate	28	30	34	29	29	34	15.3	18.5
Advanced diploma/diploma	25	26	41	20	25	23	13.3	10.1
Bachelor's degree	59	40	48	59	51	49	25.4	20.6
Graduate diploma/certificate	14	16	11	13	12	16	6.8	10.1
Postgraduate	22	29	21	24	23	19	11.5	8.5
Other	1	1	0	2	1	0	0.4	-
<b>Country of Birth</b>								
Australia	151	152	156	167	160	162	78.7	65.6
Overseas	50	48	45	34	40	39	28.3	34.4
<b>Gender</b>								
Woman	103	99	94	102	106	104	50.5	50.7
Man	98	101	105	99	94	97	49.3	49.3
Non-binary / other	0	0	2	0	0	0	0.2	-
<b>Age bracket (years)</b>								
18-24	20	24	20	22	21	19	10.5	12.1
25-34	33	39	51	42	37	35	19.7	20.6
35-44	39	41	27	38	33	32	17.4	19.3
45-54	36	29	30	33	37	37	16.8	18.0
55-64	28	29	31	25	36	30	14.9	16.6
65+	45	38	42	41	36	48	20.8	13.3
<b>Vaccine / COVID-19 History</b>								
<b>Previous COVID-19 Vaccine</b>								
AstraZeneca (both doses)	84	84	84	84	83	84	41.8	-

Pfizer (both doses)	116	115	116	116	116	115	57.6	-
AstraZeneca and Pfizer (combination)	1	1	1	1	1	2	06	-
<b>Months since last COVID-19 vaccination</b>								
0-5	188	185	183	176	185	180	91.1	-
6-15	12	13	15	22	12	19	7.7	-
16-20	1	2	3	3	3	2	1.2	-
<b>COVID-19 Exposure: Personal infection</b>								
Yes	7	4	5	2	6	3	2.2	-
No	194	196	196	199	194	198	97.8	-
<b>COVID-19 Exposure: Significant others</b>								
Yes	28	24	24	25	21	24	12.1	-
No	173	176	177	176	197	177	89.4	-
<b>Previously heard of the Pfizer COVID-19 vaccine</b>								
Yes	198	198	198	196	198	200	98.7	-
No	3	2	3	5	2	1	1.3	-
<b>Previous heard of the Moderna COVID-19 vaccine</b>								
Yes	183	185	181	178	174	187	90.4	-
No	18	15	20	23	26	14	9.6	-

196



197

198 Figure 3: Geospatial data with participant frequency plotted against SA4 postal regions in  
199 Australia

200

201

### ***Manipulation Checks***

202

As expected, side effect familiarity was greater for the Pfizer than Moderna vaccine

203

( $t(1203)=28.63, p<.0001, \text{Cohen's } d_z=.83$ ). During the intervention, more participants


204 underestimated side effects for the Moderna ( $N=118$ ) relative to Pfizer ( $N=65$ ) vaccine ( $\chi^2(1) =$   
205  $18.97, p < .0001$ ), due to the vaccine having a higher incidence of side effects than Pfizer.

### 206 *Primary Analysis*


207 Booster Intentions were higher for any Framing relative to Control (Contrast1:  $F(1,$   
208  $1192)=11.56, p=.0007, \eta_p^2=.010$ ) and for Positive Framing ( $M=75.7, SE=0.9, 95\% CIs[73.9,$   
209  $77.4]$ ) relative to Negative Framing ( $M=70.7, SE=0.9, 95\% CIs[68.9, 72.4]$ ;  $F(1, 1192)=4.68,$   
210  $p=.031, \eta_p^2=.004$ ). As presented in Figure 4a, the anticipated Framing\*Vaccine interaction was  
211 not significant at Contrast2 (Positive vs. Negative:  $F(1, 1192)=3.31, p=.069, \eta_p^2=.003$ ), but was  
212 at Contrast1 (Framing vs. Control:  $F(1, 1192)=8.91, p=.003, \eta_p^2=.007$ ), with the effect of any  
213 information over Control larger for the Unfamiliar vaccine (see S1.6 for full model output and  
214 means).

215 As in Figure 4b, a three-way Framing\*Vaccine\*Baseline Intention interaction was  
216 present at both Contrasts (Control vs. Framing:  $F(1, 1192)=7.39, p=.007, \eta_p^2=.006$  | Positive vs.  
217 Negative:  $F(2, 1192)=5.26, p=.022, \eta_p^2=.004$ ). For the less familiar Moderna vaccine, Positive  
218 Framing ( $M=94.92, SE=1.88, 95\% CI[91.24, 98.60]$ ) increased Booster Intention relative to  
219 Negative Framing ( $M=87.18, SE=1.95, 95\% CI[83.35, 91.0]$ ) at high Baseline Intent  
220 (VAS=100). For the more familiar Pfizer vaccine, Positive Framing ( $M=24.03, SE=4.29, 95\%$   
221  $CI[15.62, 32.4]$ ) increased Intention at low Baseline Intent (VAS=0) relative to Negative  
222 Framing ( $M=9.42, SE=4.54, 95\% CI[0.51, 18.3]$ ). Results appeared not to be driven by greater  
223 underestimation for the less familiar Moderna vaccine (see: S1.7).

4a. Booster Intention (Framing\*Familiarity)



4b. Booster Intention (Framing\*Familiarity\*Baseline Intention)



Key: Framing — Positive Frame — Negative Frame — No Intervention Control

224  
225 Figure 4: Model estimated mean differences in the primary outcome (Booster Intention). 4a  
226 depicts mean Booster Intention for each framing condition by vaccine type. 4b depicts the  
227 Framing\*Familiarity\*Baseline Booster Intention interaction. All error bars represent ± 1SEM.  
228

### 229 *Secondary-Predictors: Mediation*

230 Positive Framing is theorised to create a valence-consistent shift in perceptions that  
231 alters evaluation and intention<sup>16,17</sup>. Analysis was therefore run to explore whether side effect  
232 perceptions mediated the effect of framing (Positive vs. Negative) on Booster Intentions across  
233 vaccines (i.e., as if the intervention were generally applied). Three models were run with  
234 baseline-corrected Booster Intention (change score) as the outcome and baseline-corrected  
235 secondary predictors as mediators. As in Table 2, partial mediation was observed through a  
236 decrease in Side Effect Worry and Severity associated with Positive Framing. This was specific  
237 to side effect perceptions and not significant for Booster Protection.

238

239 Table 2: Mediation of Framing (Positive vs. Negative) on Booster Intention through Side Effect  
 240 Worry, Perception of Side Effect Severity, and Perceived Booster Protection. Paths a and b  
 241 represent paths from predictor to mediator and mediator to outcome. Path c represents the total  
 242 effect (Framing on Booster Intention), c' the association between Framing and Booster Intention  
 243 controlling for all other paths, and a\*b indirect effect of the mediator on the Framing – Booster  
 244 Intention association. Bias-corrected bootstrapped 95% CIs (10,000 samples) are presented.  
 245

A) Mediation Model: Side Effect Worry

	$\beta$	<i>B</i>	<i>SE B</i>	<i>Z</i>	<i>p</i>	95% CIs
a	-0.14	-6.51	1.66	-3.92	<b>&lt;.001</b>	[-9.85, -3.36]
b	-0.18	-0.15	0.04	-3.77	<b>&lt;.001</b>	[-0.18, -0.18]
c	0.10	3.93	1.37	2.87	<b>.004</b>	[1.22, 6.55]
c'	0.08	2.98	1.34	2.23	<b>.026</b>	[0.33, 5.56]
a*b	0.02	0.95	0.35	2.68	<b>.007</b>	[0.40, 1.82]

B) Mediation Model: Perceived Side Effect Severity

	$\beta$	<i>B</i>	<i>SE B</i>	<i>Z</i>	<i>p</i>	95% CIs
a	-0.20	-8.63	1.48	-5.83	<b>&lt;.001</b>	[-11.54, -5.66]
b	-0.20	-0.18	0.05	-3.67	<b>&lt;.001</b>	[-0.29, -0.09]
c	0.10	3.93	1.37	2.87	<b>.004</b>	[1.22, 6.55]
c'	0.06	2.34	1.37	1.71	.088	[-0.36, 4.99]
a*b	0.04	1.59	0.52	3.02	<b>.002</b>	[0.04, 0.08]

C) Mediation Model: Perceived Booster Protection

	$\beta$	<i>B</i>	<i>SE B</i>	<i>Z</i>	<i>p</i>	95% CIs
a	0.05	1.74	1.16	1.50	.134	[-0.53, 3.99]
b	0.32	0.38	0.06	5.88	<b>&lt;.001</b>	[0.25, 0.50]
c	0.10	3.93	1.37	1.47	<b>.004</b>	[1.22, 6.55]
c'	0.09	3.28	1.30	2.52	<b>.012</b>	[0.70, 5.75]
a*b	0.02	0.66	0.45	1.47	.143	[-0.15, 1.62]

246

247

248

**Discussion**

249

250

251

252

253

254

The present study tested an intervention involving the presentation of framed side-effect information. Overall, providing side effect information of any type to participants increased their COVID-19 Booster Intention relative to the Control group, who received no information at all. Of note, Positive Framing further increased Booster Intention relative to Negative Framing by 5 percentage points. While the mapping between intention and uptake is unlikely to be exact<sup>18</sup> (see below), our results suggest that Positive Framing could lead to up to half a million

255 extra booster vaccinations among those aged 18 and over (based on population averages from  
256 the ABS Education and Work Dataset 2021). Results therefore indicate that presenting  
257 positively-framed information to people, for example on Australian Government and  
258 AusVaxSafety websites, is likely to increase favorable perceptions of booster vaccination.

259       Based on our previous research<sup>6</sup> and the broader literature concerning framing effects on  
260 vaccine-related intentions<sup>7,8</sup>, vaccine familiarity was anticipated to modulate the effect of  
261 Positive Framing. However, Booster Intention after Positive Framing was only numerically, not  
262 statistically, larger for the less familiar Moderna vaccine compared to Negative Framing.  
263 Instead, we found that both Positive and Negative provided an increased benefit to Booster  
264 Intention over Control for the less familiar Moderna vaccine relative to the more familiar Pfizer  
265 vaccine (although this appeared to be driven by the Positive Framing manipulation). A three-  
266 way interaction involving Baseline Intention qualified these effects. Here, the difference  
267 between Positive and Negative Framing was largest at low levels of Baseline Intent for the  
268 Familiar vaccine, but at high levels of Baseline Intent for the Unfamiliar vaccine. In our  
269 previous research, Positive Framing was found to decrease Booster Intention relative to  
270 Negative Framing for familiar vaccines<sup>6</sup>. Notably, this was not the case here. Several  
271 differences exist between these studies, such as sample location, number of framed side effects,  
272 and the mode of presentation (PILs vs. infographics). As such, future research should strive to  
273 understand the conditions under which Positive Framing reduces vaccine intention to ensure that  
274 optimal messaging is employed.

275       Population level public health information on side effects is inherently general and  
276 cannot contain nuanced information about the influence of prior history of vaccination or  
277 hesitancy. While a complex pattern of results was observed, Positive Framing was always either  
278 superior, or equal to, Negative Framing and Control at all levels of Baseline Intent for both  
279 vaccines. Moreover, at differing levels of Baseline Intent, Negative Framing decreased Booster  
280 Intention relative to Positive Framing for both familiar and less familiar vaccines. Among those

281 most resistant to vaccination, Positive Framing of the more familiar vaccine (Pfizer) increased  
282 Booster Intention by 14.6 percentage-points relative to Negative Framing, and by 19.8  
283 percentage-points relative to Control for the less familiar vaccine (Moderna). As such, there was  
284 never any disadvantage to employing Positive Framing in the present sample, even when  
285 targeting those with low Baseline Intent; a population where increasing vaccine acceptance is of  
286 critical importance<sup>19</sup>. This suggests that Positive Framing is the optimal presentation mode.

287 In terms of mechanisms, theories of attribute framing posit that Positive Framing results  
288 in a valence-consistent shift in perception that alters evaluation<sup>16,17</sup>. We therefore reasoned that  
289 Positive Framing would alter side effect perception, increasing intention to be vaccinated.  
290 Mediation analysis provided tentative support for this theory. Specifically, a reduction in the  
291 perception of side effect severity and side effect worry partially mediated the effect of Positive  
292 (vs. Negative) Framing on Booster Intention, suggesting that Framing may indeed reduce side  
293 effect hesitancy. Mediation was not found through perceived booster protection, with the  
294 association between Framing and booster protection weaker than with side effect perceptions  
295 (severity and worry).

296 There are several strengths to the present study, including the framing of real COVID-19  
297 vaccines and the use of actual side effect data presented to the Australian population. Especially  
298 as much of the literature in this area frames fictitious vaccines and asks participants to imagine  
299 scenarios that they have never experienced and may be unlikely to ever experience<sup>7,8,12,17,20</sup>.  
300 Limitations of the study include the measurement of intention, but not uptake. While intention  
301 has been found to predict vaccination<sup>21-24</sup>, longitudinal research is needed to directly assess the  
302 role of framing on actual uptake, as well as the longevity of the framing effect among those yet  
303 to receive a booster vaccine. Relevant to the lag in booster uptake in Australia<sup>25</sup>, the present  
304 research focused on increasing intention among those already receiving a primary course of  
305 COVID-19 vaccination. However, these results do not speak to the effect of framing on those  
306 never vaccinated. Investigation of framing on vaccine intention at all points of the vaccination



307 programme would provide a more comprehensive account of the effect of framing on vaccine  
308 intentions in general.

309           In summary, a brief online intervention engaging participants in side effect estimation  
310 before presenting positively framed side effect information can increase booster vaccine  
311 intention. Given the ease with which Positive Framing can be implemented, combined with the  
312 fact that the presentation of statistical information in this format does not violate patient  
313 informed consent<sup>9</sup>, the potential exists for framing of this type to make a real difference in  
314 improving societal protection from COVID-19 through reduced vaccine hesitancy.

315 **Sources of Funding:** This research was supported by Australian Research Council grants  
316 DP180102061 and DP200101748. The funding body had no involvement in study design,  
317 analysis, interpretation, writing, or the decision to submit the present article for publication.

318

319 **Data Availability:** The code and raw data necessary to replicate the reported analysis is  
320 available through the Open Science Framework repository:

321 [https://osf.io/nfxr3/?view\\_only=e0717d3f063245268f8ce88144afaa3f](https://osf.io/nfxr3/?view_only=e0717d3f063245268f8ce88144afaa3f)

322

323 **Author contributions:** KB, BC and KF conceived the experimental design. KB was  
324 responsible for collecting and analysing the data. KB wrote the first draft of the article. BC and  
325 KF edited and contributed to the final version.

326

327

## References

- 328 1 Solís Arce, J. S. *et al.* COVID-19 vaccine acceptance and hesitancy in low- and middle-  
329 income countries. *Nature Medicine* **27**, 1385-1394 (2021).
- 330 2 Troiano, G. & Nardi, A. Vaccine hesitancy in the era of COVID-19. *Public Health* **194**,  
331 245-251 (2021).
- 332 3 Rzymiski, P., Poniedziałek, B. & Fal, A. Willingness to Receive the Booster COVID-19  
333 Vaccine Dose in Poland. *Vaccines* **9**, 1286 (2021).
- 334 4 Chevallier, C., Hacquin, A.-S. & Mercier, H. COVID-19 Vaccine Hesitancy: Shortening  
335 the Last Mile. *Trends in Cognitive Sciences* **25**, 331-333 (2021).
- 336 5 *World Health Organization. Data for action: achieving high uptake of COVID-19*  
337 *vaccines: gathering and using data on the behavioural and social drivers of*  
338 *vaccination: a guidebook for immunization programmes and implementing partners:*  
339 *interim guidance, 1 April 2021.* (World Health Organization, Geneva, 2021);  
340 <https://apps.who.int/iris/handle/10665/340645>
- 341 6 Barnes, K. & Colagiuri, B. Positive attribute framing increases COVID-19 booster  
342 vaccine intention for unfamiliar vaccines. Preprint at:  
343 <https://www.medrxiv.org/content/10.1101/2022.01.25.22269855v2> (2022).
- 344 7 Donovan, R. J. & Jalleh, G. Positive versus Negative Framing of a Hypothetical Infant  
345 Immunization: The Influence of Involvement. *Health Education & Behavior* **27**, 82-95  
346 (2000).
- 347 8 Haydarov, R. & Gordon, J. C. Effect of combining attribute and goal framing within  
348 messages to change vaccination behavior. *Journal of Communication in Healthcare* **8**,  
349 45-54 (2015).
- 350 9 Barnes, K. *et al.* Can Positive Framing Reduce Nocebo Side Effects? Current Evidence  
351 and Recommendation for Future Research. *Frontiers in Pharmacology* **10**, 167 (2019).
- 352 10 Shimabukuro, T. T., Cole, M. & Su, J. R. Reports of Anaphylaxis After Receipt of  
353 mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021. *JAMA*  
354 **325**(11), 1101–1102 (2021).
- 355 11 Diaz, G. A. *et al.* Myocarditis and Pericarditis After Vaccination for COVID-19. *JAMA*  
356 **326**(12), 1210–1212 (2021).
- 357 12 Webster, R. K. & Rubin, G. J. The Effect of Positively Framing Side-Effect Risk in Two  
358 Different Formats on Side-Effect Expectations, Informed Consent and Credibility: A  
359 Randomised Trial of 16- to 75-Year-Olds in England. *Drug Safety* **43**, 1011–1022  
360 (2020).

- 361 13 Berry, D. C., Raynor, D. K. & Knapp, P. Communicating risk of medication side effects:  
362 An empirical evaluation of EU recommended terminology. *Psychology, Health &*  
363 *Medicine* **8**, 251-263 (2003).
- 364 14 Myers, J. L. & Well, A. D. *Research design and statistical analysis, 2nd ed.* (Lawrence  
365 Erlbaum Associates Publishers, 2003).
- 366 15 Cardinal, R. N. & Aitken, M. R. F. *ANOVA for the behavioural sciences researcher.*  
367 (Lawrence Erlbaum Associates Publishers, 2006).
- 368 16 Levin, I. P., Schneider, S. L. & Gaeth, G. J. All Frames Are Not Created Equal: A  
369 Typology and Critical Analysis of Framing Effects. *Organizational Behavior and*  
370 *Human Decision Processes* **76**, 149-188 (1998).
- 371 17 Krishnamurthy, P., Carter, P. & Blair, E. Attribute Framing and Goal Framing Effects in  
372 Health Decisions. *Organizational Behavior and Human Decision Processes* **85**, 382-399  
373 (2001).
- 374 18 Sheeran, P. Intention—Behavior Relations: A Conceptual and Empirical Review.  
375 *European Review of Social Psychology* **12**, 1-36 (2002).
- 376 19 *Ten threats to global health in 2019* (World Health Organisation, 2019);  
377 <https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019>
- 378 20 Zimmermann, C., Baldo, C. & Molino, A. Framing of outcome and probability of  
379 recurrence: Breast cancer patients' choice of adjuvant chemotherapy (ACT) in  
380 hypothetical patient scenarios. *Breast Cancer Research and Treatment* **60**, 9-14 (2000).
- 381 21 Gerend, M. A. & Shepherd, J. E. Predicting Human Papillomavirus Vaccine Uptake in  
382 Young Adult Women: Comparing the Health Belief Model and Theory of Planned  
383 Behavior. *Annals of Behavioral Medicine* **44**, 171-180 (2012).
- 384 22 Juraskova, I., Bari, R. A., O'Brien, M. T. & McCaffery, K. J. HPV Vaccine Promotion:  
385 Does Referring to Both Cervical Cancer and Genital Warts Affect Intended and Actual  
386 Vaccination Behavior? *Women's Health Issues* **21**, 71-79 (2011).
- 387 23 Lehmann, B. A., Ruiter, R. A. C., Chapman, G. & Kok, G. The intention to get  
388 vaccinated against influenza and actual vaccination uptake of Dutch healthcare  
389 personnel. *Vaccine* **32**, 6986-6991 (2014).
- 390 24 Jensen, U. T., Ayers, S. & Koskan, A. M. Video-based messages to reduce COVID-19  
391 vaccine hesitancy and nudge vaccination intentions. *PLOS ONE*, **17**(4) e0265736  
392 (2022).
- 393 25 Nicholas, J. Tracking Australia's booster rollout: data shows millions of eligible  
394 Australians yet to get third Covid vaccine dose. *The Guardian* (Australia) 2022; 17

395 March. [https://www.theguardian.com/australia-news/australia-](https://www.theguardian.com/australia-news/australia-datablog/2022/mar/17/tracking-australias-booster-rollout-data-shows-millions-of-eligible-australians-yet-to-get-third-covid-vaccine-dose)  
396 [datablog/2022/mar/17/tracking-australias-booster-rollout-data-shows-millions-of-](https://www.theguardian.com/australia-news/australia-datablog/2022/mar/17/tracking-australias-booster-rollout-data-shows-millions-of-eligible-australians-yet-to-get-third-covid-vaccine-dose)  
397 [eligible-australians-yet-to-get-third-covid-vaccine-dose](https://www.theguardian.com/australia-news/australia-datablog/2022/mar/17/tracking-australias-booster-rollout-data-shows-millions-of-eligible-australians-yet-to-get-third-covid-vaccine-dose) (accessed March 2022).